11/8/2005

1. In Vivo Differentiation of Stem Cell and Their Progeny
Robert Lanza, MD
VP Medical & Scientific Development
Advanced Cell Technology
Adjunct Professor
Institute of Regenerative Medicine
Wake Forest University School of Medicine

2. CAUTIONARY STATEMENT
CONCERNING FORWARD-LOOKING STATEMENTS
This presentation contains “forward-looking statements” as defined under the
federal securities laws. Actual results could vary materially. Factors that
could cause actual results to vary materially are described in our filings with
the Securities and Exchange Commission. You should pay particular attention
to the “risk factors” contained in documents we file from time to time with the
Securities and Exchange Commission. The risks identified therein, as well as
others not identified by the Company, could cause the Company’s actual
results to differ materially from those expressed in any forward-looking
statements.

3. Alzheimer’s
Dwarfism
Parkinson’s
Strokes
Epilepsy
Hemophilia
Kidney failure
Chronic pain
Cancer
Infertility
Burns
AIDS
Muscular dystrophy
ALS
Affective disorders
Macular degeneration
Hypoparathyroidism
Heart disease
Liver failure
Enzymatic defects
Diabetes
Osteoarthritis
Multiple sclerosis
Huntington’s
Hypocholesterolemia
Rheumatoid
arthritis
Atherosclerosis
Ulcers
Spinal cord
injuries

4. 10
20
30
40
50
60
70
1988
1989
1990
1991
1992
1993
1994
1995
1996
1997
1998
Year
NumberofPatients(inthousands)
Waiting List
Organs Transplanted

5. Stem cells are smart
• In vitro: Without the right environmental clues they don’t know what
we want them to do. Left to their own devices in vitro, they
differentiate into a hodgepodge of cell types – neurons, heating heart
cells, ciliated epithelium, and even miniature “eyeballs”
• In vivo: Stem cells home towards damaged tissue where they can
initiate tissue regeneration. We need a better grasp of the roles played
by such chemical signals as insulinlike growth factor (IGF-1), which
may also take part in causing local cells to revert to a multipotent state
and begin differentiating into the required tissue types. This
phenomena (epimorphic regeneration) underlies the ability of newts &
zebrafish to regrow limbs and organs.

6. •Parkinson’s ($6 billion/yr)
•Stroke ($45 billion/yr)
•Spinal cord injury ($10 billion/yr)
•Epilepsy ($3 billion/yr)
•Alzheimer’s ($100 billion/yr)
•Multiple sclerosis ($10 billion/yr)

11. Generation of ES cells using parthenogenesis

16. WBC colony from cloned stem cells

17. •Cardiovascular disease costs the US $329 billion annually

18. ~ Biodegradable scaffolds
~ Self-assembly

21. End-stage renal disease will cost US $1 trillion during the coming
decade

23. A few last thoughts
• Moving into the clinic – perhaps the damaged tissue area can do part
of the work for us
• More basic research – we need to better understand the in vivo factors
that control stem cell fate and repair
• Regenerative medicine’s ideal – to find a means to cause controlled
de- and trans- differentiation of cells in adult tissue. Will it ever be
possible to generate an environment that replicates the ability of newts
and zebra fish to regenerate tissue, to regrow entire limbs and organs?
•